Zhijie Pan

机构：Ningbo University, Chinese Academy of Sciences, The First People's Hospital of Zhaoqing, Electro Magnetic Applications (United States), Ningbo Institute of Industrial Technology, First Affiliated Hospital Zhejiang University · ORCID：0000-0002-7605-780X

发表论文 67 篇 · 总被引 1062 次 · h-index 16

代表论文

• First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial (2025 · 癌症：英文版 · 被引 21)
• How green screening influences risk transmission among stock-bond indices: Insight into the dependence structure (2024 · Finance research letters · 被引 18)
• Multimodal Feature Fusion for Bone Toxicity Prediction and Local Platform (2025 · Journal of Chemical Information and Modeling · 被引 17)
• Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial (2025 · The Lancet Respiratory Medicine · 被引 13)
• Risk stratification of thymic epithelial tumors based on peritumor CT radiomics and semantic features (2024 · Insights into Imaging · 被引 6)
• Serplulimab vs. placebo combined with chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Extended follow-up results and patient-reported outcomes from the international phase 3 ASTRUM-005 study. (2024 · Journal of Clinical Oncology · 被引 6)